Compounds > 9-methoxycamptothecin
Page last updated: 2024-11-07

9-methoxycamptothecin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

10-methoxycamptothecin: a radiotracer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

9-methoxycamptothecin: RN given refers to (S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID97283
CHEMBL ID75854
SCHEMBL ID1035263
MeSH IDM0085442
PubMed CID123617
CHEMBL ID522112
SCHEMBL ID1004508
MeSH IDM0085442

Synonyms (48)

Synonym
CHEMBL75854
19685-10-0
10-methoxycamptothecin
1h-pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-9-methoxy-, (s)-
nsc-111533
NCI60_000257
1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-9-methoxy-, (s)-
nsc 111533
SCHEMBL1035263
Q-100242
(s)-10-methoxycamptothecin, aldrichcpr
AKOS030573697
10-methoxycamptothecine
DTXSID60941445
A14767
HY-N0446
CS-0008979
MS-26165
(19s)-19-ethyl-19-hydroxy-7-methoxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
E88614
PD164882
camptothecin, 9-methoxy-
9-methoxycamptothecin
39026-92-1
nsc-176323
1h-pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione-, 4-ethyl-4-hydroxy-10-methoxy-, (s)-
NSC176323 ,
camptothecin,9-methoxy
NCI60_001450
{1h-pyrano[3',} {4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione-,} 4-ethyl-4-hydroxy-10-methoxy-, (s)-
CHEMBL522112
nsc 176323
SCHEMBL1004508
DTXSID00192292
ncgc00385478-01_c21h18n2o5_1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-10-methoxy-, (4s)-
NCGC00385478-01
AKOS037514539
F17695
XVMZDZFTCKLZTF-NRFANRHFSA-N
mfcd03840473
ZB1864
(s)-4-ethyl-4-hydroxy-10-methoxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
(19s)-19-ethyl-19-hydroxy-8-methoxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
HY-N6011
CS-0032150
MS-26164
(s)-4-ethyl-4-hydroxy-10-methoxy-1,12-dihydro-14h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h)-dione
PD125185

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID152255Antileukemic activity against P-388 leukemia cells was measured at given dose range1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID235764Therapeutic index was measured on P-388 leukemia cells.1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID152097Compound was evaluated for antitumor activity against P-338 leukemia in mice at the dose of 1.6 mg/kg; T/C=Survival time of treated/control animals*1001986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID152114Compound was evaluated for antitumor activity against P-338 leukemia in mice, active dose range of the compound; Lowest dose administered, dose range was 0.4-1.6 mg/kg1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID426063Antitumor activity against human HT-29 cells by SRB method2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.
AID152245Antitumor activity against P-338 leukemia in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID426062Antitumor activity against human A549/ATCC cells by SRB method2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.
AID152254This is the dose at which optimal activity was observed against P-388 leukemia cells1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID152253Lowest toxicity was observed at this dose against P-388 leukemia cells1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID120239Optimal activity expressed as percentage treated to that of control was measured in vivo against P-388 leukemia cells1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID152247Antitumor activity against P-338 leukemia in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
AID8446In vitro cytotoxicity of compound was tested against 9KB cells.1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID337695Antibacterial activity against Escherichia coli ATCC 25922 at 5 ug after 48 hrs by silica gel plate-based INT-formazan method
AID337694Antibacterial activity against Bacillus subtilis ATCC 6633 at 5 ug after 48 hrs by silica gel plate-based INT-formazan method
AID381253Cytotoxicity against mouse P388 cells
AID381252Cytotoxicity against human KB cells
AID380079Cytotoxicity against human A2780 cells by clonogenic assay2006Journal of natural products, Feb, Volume: 69, Issue:2
Cytotoxic and other compounds from Didymochlaena truncatula from the Madagascar rain forest.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.70)18.7374
1990's0 (0.00)18.2507
2000's7 (30.43)29.6817
2010's11 (47.83)24.3611
2020's3 (13.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.78 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
LSM-1442
[no description available]		1.9510pyranoindolizinoquinoline
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		3.4170delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.0510pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
9-aminocamptothecin
[no description available]		1.9610pyranoindolizinoquinoline
10-hydroxycamptothecin
[no description available]		3.2760pyranoindolizinoquinoline
sn 38
SN-38 : A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.		2.0510delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol		antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
7-ethyl-7-hydroxy-10h-1,3-dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7h,12h)-dione
7-ethyl-7-hydroxy-10H-1,3-Dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7H,12H)-dione: an antineoplastic agent that inhibits survivin, Mcl-1, and cIAP2; structure in first source		1.9610
rubitecan
rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.		1.9610C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
nsc 100880
[no description available]		1.9510
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		4130delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
10-hydroxycamptothecin
[no description available]		7.7830pyranoindolizinoquinoline
Pinosylvin methyl ether
[no description available]		2.0310stilbenoid
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9610
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9510
Colorectal Cancer
[description not available]		02.0510
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0510
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.1110
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Benign Neoplasms
[description not available]		02.110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.110